A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED, FIRST-IN-HUMAN STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SINGLE ASCENDING ORAL DOSES OF PF-07258669 ADMINISTERED TO HEALTHY ADULT PARTICIPANTS
Latest Information Update: 23 Feb 2024
At a glance
- Drugs PF 07258669 (Primary)
- Indications Anorexia
- Focus Adverse reactions; First in man
- Sponsors Pfizer
- 07 Sep 2021 Status changed from recruiting to completed.
- 12 Aug 2021 According to a Sosei Heptares media release, the company has received the $5 million payment from Pfizer on dosing of first subject in the study.
- 19 Apr 2021 Planned End Date changed from 29 Aug 2021 to 18 Aug 2021.